Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post Q4 2025 Earnings of $0.65 Per Share, Zacks Research Forecasts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities researchers at Zacks Research decreased their Q4 2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued to investors on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.65 per share for the quarter, down from their previous forecast of $0.66. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q1 2026 earnings at $0.76 EPS and FY2026 earnings at $3.45 EPS.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Bank of America started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 target price for the company. Finally, Oppenheimer restated an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $14.89 on Thursday. The business’s 50 day moving average is $15.52 and its two-hundred day moving average is $14.61. Catalyst Pharmaceuticals has a 1-year low of $11.09 and a 1-year high of $17.76. The stock has a market capitalization of $1.76 billion, a P/E ratio of 24.07, a PEG ratio of 0.83 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The company had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares in the company, valued at $2,045,678.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.10% of the stock is owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Parkside Financial Bank & Trust purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $31,000. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 819 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 306.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 3,829 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Catalyst Pharmaceuticals by 84.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,833 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth $123,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.